New order-processing line: automated handling cell and roller conveyor now being commissioned at CosmoFarm's distribution center in Peristeri, Athens, designed to move more orders through the facility in less
Amazon UK sales up 90%: $2.27 million in TTM sales for the twelve months to November 2, 2026, up from approximately $1.19 million in the prior twelve months23% net margin on Amazon UK: the Amazon UK channel generated
Active subscriptions up 92%: 12,050 active U.S. subscriptions as of October 28, 2026, up from 6,287 on October 14, 2026Monthly subscription value up 94%: $1,787,585 at standard renewal pricing as of October 28, 2026, up
Rating and price target: Outperform rating with a $1.40 price targetImplied upside: approximately 493% above the $0.236 closing price on Tuesday, October 27, 2026Valuation basis: 1.42 times Noble's 2027 revenue
Now live in Oceania: e-commerce subscription business operating across Australia, New Zealand and the broader Oceania region, with sales already underwayAttractive markets: together, Australia and New Zealand represent
Key HighlightsRecord revenue: preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, with every quarter of 2026 setting a record2026 outlook reaffirmed: full-year revenue expected to surpass $90
● Q4 2026 U.S. revenue: approximately $15 million expected, based on the Company's current growth trajectory● Q4 2026 gross profit: approximately $10.5 million expected, at an approximately 70% gross margin●
● 6,287 active U.S. subscriptions as of October 14, 2026, the vast majority added since mid-September as the Company accelerates investment in its U.S. platform● 60.5% of U.S. online checkout orders included a
Record day: U.S. direct-to-consumer sales exceeded $92,000 on October 11, 2026, the highest single day to date$902,000 in 30 days: approximately $30,000 in average daily sales over the trailing 30-day
Record nine-month revenue of approximately $54.3 million - up 19%, or $8.7 million, from $45.6 million in the same period of 2025Nine-month 2026 revenue nearly matches the whole of 2024 - when full-year revenue was
More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin care and mother & baby, and branded genericsProprietary brands sold
Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarmRevenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full
Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreementsGross margins of
7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million todaySecured orders for 1.04 million units
Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stockPositions Cosmos Health among the
